TDRKH-AS1: A promising drug target and biomarker for treating human diseases

Target Name: TDRKH-AS1

NCBI ID: G109729141

TDRKH-AS1

Other Name(s): TDRKH antisense RNA 1, transcript variant 1 | TDRKH antisense RNA 1

TDRKH-AS1: A promising drug target and biomarker for treating human diseases

Abstract:

TDRKH-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for treating various human diseases. Its unique structure, function, and bioavailability make it an attractive candidate for further study. This article will provide an overview of TDRKH-AS1, its potential drug target status, and its potential as a biomarker for various human diseases.

Introduction:

The translation of RNA into protein is a critical process in the development of new drugs and therapies. One of the challenges in this process is the regulation of gene expression, which can be influenced by various factors, including post-transcriptional modifications, RNA levels, and interactions with protein(s). TDRKH-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for treating various human diseases.

Structure and function:

TDRKH-AS1 is a non-coding RNA molecule that contains 189 amino acid residues. It has a unique structure, with a 5'-end that is rich in conserved amino acid sequence, a 3'-end that is conserved in sequence, and a middle region that is rich in un conserved amino acid sequences. This structure allows TDRKH-AS1 to interact with various protein(s) and participate in various signaling pathways.

TDRKH-AS1 functions as an RNA molecule that can interact with protein(s) to regulate gene expression. It has also been shown to play a role in various signaling pathways, including cell growth, apoptosis, and inflammation. to interact with protein(s) involved in diseases such as cancer, neurodegenerative diseases, and psychiatric disorders.

Potential drug target status:

TDRKH-AS1 has been identified as a potential drug target due to its unique structure, function, and bioavailability. Its 5'-end and 3'-end conserved amino acid sequences make it accessible to various drug molecules, while its middle region rich in un Conserved amino acid sequences make it responsive to various signaling pathways. Additionally, its unique structure allows it to interact with various protein(s) involved in disease processes, providing a potential mechanism for its drug targeting properties.

Potential as a biomarker:

TDRKH-AS1 has the potential to serve as a biomarker for various human diseases. Its unique structure and function make it sensitive to various signaling pathways, providing potential for its use in disease biomarkers. For example, TDRKH-AS1 has been shown to be involved in cancer progression, and its levels have been shown to be elevated in various cancer types. Its potential as a drug target also makes it a potential biomarker for neurodegenerative diseases.

Conclusion:

TDRKH-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for treating various human diseases. Its unique structure, function, and bioavailability make it an attractive candidate for further study. Further research is needed to determine its potential as a drug target and biomarker, and to develop effective therapies based on its unique properties.

Protein Name: TDRKH Antisense RNA 1

The "TDRKH-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TDRKH-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets